Watchlist
Dow 24,596.59 -156.50 -0.63%
S&P 500 2,706.46 -14.87 -0.55%
Nasdaq 7,422.96 -10.89 -0.15%
GlobalDow 3,010.75 -25.33 -0.83%
Gold 1,300.50 -8.50 -0.65%
Oil 67.12 -0.76 -1.12%
AGNUSOpenBack To Top
Last Updated: May 29, 2018 10:18 a.m. EDT Real time quote

$ 151.74

-2.26 -1.47%
Previous Close
$154.00
Advanced Charting
  • $
  • %
  • Vol
Advanced Charting
7.449% vs Avg.
Volume: 229.7K 65 Day Avg. - 3.1M
Open: 152.37
Last: 151.74
151.17 Day Low/High 152.86
Day Range
142.81 52 Week Low/High 256.80

Your Watchlist

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

Symbol
Company
Price
Chg/Chg %
No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

Create a list of the investments you want to track.

Uh oh

Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Key Data

  • Open $152.37
  • Day Range 151.17 - 152.86
  • 52 Week Range 142.81 - 256.80
  • Market Cap $52.22B
  • Shares Outstanding 345.73M
  • Public Float 344.68M
  • Beta 1.09
  • Rev. per Employee $901.12K
  • P/E Ratio n/a
  • EPS $-6.75
  • Yield 1.90%
  • Dividend $0.72
  • Ex-Dividend Date May 17, 2018
  • Short Interest 5.71M 05/15/18
  • % of Float Shorted 1.66%
  • Average Volume 3.08M

Performance

5 Day
  • -2.70%
1 Month
  • 0.44%
3 Month
  • -1.61%
YTD
  • -7.24%
1 Year
  • -32.18%

Recent News

  • MarketWatch
  • Other Dow Jones

Allergan recalls birth control that erroneously swapped placebo for contraceptive pills

Allergan PLC is recalling one lot of the birth control Taytulla because the first four days of the therapy erroneously placed placebo pills where contraceptive capsules should have been. The out-of-order pills might not be evident to women using the product, including previous users and new users, and thus could result in unintended pregnancy. Patients concerned about this should consult their doctor, Allergan said. The packaging error affected one lot of Taytulla, according to Allergan, a "physicians sample pack" that was distributed nationwide. (The lot, numbered 5620706, contains 28 pills and expires in May 2019.) The issue was discovered because of a physician report, Allergan said. Birth control pills must be taken faithfully each day in order to work effectively, experts say; one reproductive health professor told MarketWatch last year, "it only takes missing a couple of birth control pills for a person to become pregnant." Allergan shares declined 0.7% premarket. Shares have slumped 0.14% over the last three months, compared with a 0.3% rise in the S&P 500 and a 1.1% drop in the Dow Jones Industrial Average .

Allergan recalls birth control that erroneously swapped placebo for contraceptive pills

Allergan recalls birth control that erroneously swapped placebo for contraceptive pills

Allergan issues recall on Taytulla contraceptives

Allergan issues recall on Taytulla contraceptives

Why Trump’s drug-price pitch makes no sense
Opinion

Why Trump’s drug-price pitch makes no sense

Allergan's stock surges after profit, revenue beat expectations

Shares of Allergan PLC surged 3.2% toward in premarket trade Monday, on track to swing to a year-to-date gain, after the drug maker reported first-quarter profit and sales that beat expectations. The company reported a net loss that narrowed to $332.5 million, or 99 cents a share, from $2.63 billion, or $7.86 a share, in the same period a year ago. Excluding non-recurring items, such as research and development impairments, adjusted earnings per share came to $3.74, above the FactSet consensus of $3.36. Revenue rose 2.8% to $3.67 billion, beating the FactSet consensus of $3.60 billion, as better-than-expected international brands revenue helped offset a slight miss in U.S. specialized therapeutics revenue, which includes Botox, and in-line U.S. general medicine revenue. For 2018, the company expects adjusted EPS of $15.25 to $16.00, surrounding the FactSet consensus of $15.67, and expects revenue of $15.0 billion to $15.3 billion, compared with expectations of $15.2 billion. The stock had slipped 0.9% year to date through Friday, while the S&P 500 had eased 0.1%.

Allergan's stock surges 3.1% premarket after Q1 results

Allergan's stock surges 3.1% premarket after Q1 results

Allergan sees 2018 revenue $15.0 bln-$15.3 bln; FactSet consensus $15.2 bln

Allergan sees 2018 revenue $15.0 bln-$15.3 bln; FactSet consensus $15.2 bln

Allergan sees 2018 adj. EPS $15.25-$16.00; FactSet consensus $15.67

Allergan sees 2018 adj. EPS $15.25-$16.00; FactSet consensus $15.67

Allergan Q1 revenue $3.67 bln vs. $3.57 bln; FactSet consensus $3.60 bln

Allergan Q1 revenue $3.67 bln vs. $3.57 bln; FactSet consensus $3.60 bln

Allergan Q1 adj. EPS $3.74; FactSet consensus $3.36

Allergan Q1 adj. EPS $3.74; FactSet consensus $3.36

Allergan Q1 per-share loss 99 cents vs. loss $7.86 a year ago

Allergan Q1 per-share loss 99 cents vs. loss $7.86 a year ago

European stocks slip slightly from 7-week high as consumer-goods shares struggle

European stocks slip slightly from 7-week high as consumer-goods shares struggle

FTSE 100 ends at 11-week high as pound falls on BOE rate-hike doubts

FTSE 100 ends at 11-week high as pound falls on BOE rate-hike doubts

Takeda sweetens bid for drug rival Shire

Japan's Takeda Pharmaceutical Co. said Friday it had made a sweetened proposal to buy Shire PLC after its three previous bids for the rival drugmaker that has drawn broader interest across the sector were rejected.

Takeda sweetens bid for drug rival Shire

Japan's Takeda Pharmaceutical Co. said Friday it had made a sweetened proposal to buy Shire PLC, just a day after it had a bid rejected for the rival drugmaker that has drawn broader interest across the sector.

Shire takeover has pharma rivals in feeding frenzy

Drugmaker Shire PLC has become the subject of topsy-turvy takeover interest, drawing suitors to one of few remaining biotechs with rapidly rising sales and a stock price that hasn't soared in recent months.

Blink and you missed it: Allergan doesn't plan to make a Shire bid

Capping a day of high acquisition drama, Allergan PLC has said it does not plan to make a bid for drugmaker Shire -- mere hours after saying it was considering such a bid. A play for Shire would have pitted Allergan against drugmaker Takeda Pharmaceutical Co. Ltd. , which had its about $60 billion bid for Shire rejected but has continued negotiations. Many Wall Street analysts viewed the potential Allergan-Shire deal poorly. "Combining the two undervalued companies to create value? Good for Shire, value for Allergan not clear," said Bernstein analyst Ronny Gal. Allergan shares dropped 4.4% in extremely heavy Thursday trade, to which Leerink analyst Etzer Darout noted that "investors would prefer a split or potential divestiture of parts of the business." Company shares have dropped 5.9% month-to-date, compared with a 11.3% rise in Shire shares and a 1.8% rise in the S&P 500 .

European stocks edge up as deal developments, earnings reports roll in

European stocks edge up as deal developments, earnings reports roll in

U.K. stocks finish at 10-week high as metals prices rally

U.K. stocks finish at 10-week high as metals prices rally

Allergan mulls bid for Shire after Takeda offer

A potential bidding war for drugmaker Shire PLC erupted Thursday after Japan's Takeda Pharmaceutical Co. said it made a GBP42.3 billion ($60 billion) takeover offer and U.S. rival Allergan PLC said it was considering making its own bid.

New Migraine Drugs Offer Hope to Sufferers

The FDA has approved a new drug called Aimovig that is touted as the first treatment designed specifically to prevent migraines.

  • on The Wall Street Journal

Florida and Texas Are Among Latest States to Sue Opioid Painkiller Companies

Florida and Texas, the most populous states yet to pursue litigation, join more than a dozen other states in suing opioid painkiller makers, alleging they misrepresented their drugs’ addiction risks.

  • on The Wall Street Journal

Money for Nothing

If paying a chief executive more doesn’t do anything for the company’s stock price, why pay the CEO more?

  • on The Wall Street Journal

CEO Pay and Performance Often Don’t Match Up

The best-paid CEOs don’t necessarily run the best-performing companies, and the corporations posting the best shareholder returns score in the middle of the pack in terms of CEO pay, according to a WSJ analysis.

  • on The Wall Street Journal

California Counties Jump Into Opioid Litigation

As lawsuits over the opioid crisis have spread nationwide, the country’s most populous state has largely stayed on the sidelines, but 30 California counties are now jumping in, seeking recovery for alleged taxpayer losses from the major makers and distributors of opioid painkillers.

  • on The Wall Street Journal

Takeda Wins Battle for Shire With $62 Billion Deal

Takeda reached an agreement to buy Shire, capping a monthslong battle for control of the European drugmaker and marking the biggest-ever overseas acquisition by a Japanese company.

  • on The Wall Street Journal

Ironwood Will Separate From Its Rare-Disease Drug Unit After Pressure

After pressure from shareholders and an activist investor, Ironwood Pharmaceuticals will take the unusual step of separating from a unit developing drugs for rare diseases.

  • on The Wall Street Journal

In This Earnings Season, The Beats Roll On

Analysts can’t get much sleep as first-quarter earnings continue to pour in. And they’re running out of superlatives. But investors aren’t as impressed.

  • on Barron's Online

So You Really Want to Bet on Bill Ackman?

For contrarian investors, Pershing Square Holdings—the hedge fund manager’s closed-end fund—amounts to a play on the improving fortunes of a tarnished but prominent activist.

  • on Barron's Online

Takeda Sweetens Takeover Proposal for Shire

Japan’s Takeda said it had made a sweetened proposal to buy Shire after its three previous bids for the rival drugmaker that has drawn broader interest across the sector were rejected.

  • on The Wall Street Journal

Fast-Growing Shire Had Pharmaceutical Rivals in a Takeover Frenzy

Drugmaker Shire rebuffed a takeover bid from rival Takeda Pharmaceutical, then Allergan took a look.

  • on The Wall Street Journal

Allergan Says It Won’t Make a Bid for Shire After All

Drug maker Allergan said it won’t submit an offer for rival Shire, changing its tune just hours after Allergan said it was considering such an offer.

  • on The Wall Street Journal

Worried About Your Tax Bill? Hedge-Fund Star John Paulson Owes $1 Billion

The investor’s once-in-a-lifetime bet before the financial crisis made $15 billion for his firm and $4 billion for him personally. His personal tax bill, which Mr. Paulson had deferred, is now due—just as his star is fading.

  • on The Wall Street Journal

Allergan’s Stock Is Headed for a Face-Lift

While top-selling products like Botox face major challenges, the pharma company has a promising pipeline and a bargain stock price

  • on Barron's Online

Selling Nvidia, GE, Applied Materials, Buying Pfizer

Federated Investors cut its stakes in GE, Nvidia and Applied Materials by about 20% each in Q4.

  • on Barron's Online
Board Denies Indian Tribe’s Push to End Challenge of Restasis Patents

Board Denies Indian Tribe’s Push to End Challenge of Restasis Patents

  • on The Wall Street Journal
NXP Deal Is Likely Qualcomm’s Best Defense Against Broadcom

NXP Deal Is Likely Qualcomm’s Best Defense Against Broadcom

  • on The Wall Street Journal
New Tax Law Haunts Companies That Did ‘Inversion’ Deals

New Tax Law Haunts Companies That Did ‘Inversion’ Deals

  • on The Wall Street Journal
Stocks to Watch: Boeing, Netflix, GM, Lululemon, Micron, Skyworks, Pfizer, ADM

Stocks to Watch: Boeing, Netflix, GM, Lululemon, Micron, Skyworks, Pfizer, ADM

  • on The Wall Street Journal
Allergan Names Matthew Walsh New Finance Chief

Allergan Names Matthew Walsh New Finance Chief

  • on The Wall Street Journal

Recent News

  • Other News
  • Press Releases

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2018 Update

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2018 Update

  • on Seeking Alpha

Tracking Mason Hawkins' Southeastern Asset Management Portfolio - Q1 2018 Update

Tracking Mason Hawkins' Southeastern Asset Management Portfolio - Q1 2018 Update

  • on Seeking Alpha

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

  • on Seeking Alpha

Orbimed Advisors Llc Buys Bristol-Myers Squibb Company, ARMO BioSciences Inc, Tenet Healthcare ...

Orbimed Advisors Llc Buys Bristol-Myers Squibb Company, ARMO BioSciences Inc, Tenet Healthcare Corp, Sells Eli Lilly and Co, Cigna Corp, Amgen Inc

  • on GuruFocus.com

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

  • on Seeking Alpha

Why Micron Was Tepper’s Top Buy in Q1 2018

David Tepper’s Appaloosa Management's top buys in the first quarter were Micron Technology (MU), Lam Research (LRCX), Wells Fargo (WFC), UBS (UBS), and Allergan (AGN).

  • on MarketRealist.com

Allergan Stock Down Since Q1 Earnings Report: Here's Why

Though Allergan (AGN) boasts a solid underlying business, its stock is down. Here we discuss why.

  • on Zacks.com

Allergan nabs rights to new antidepressant compound

Allergan nabs rights to new antidepressant compound

  • on Seeking Alpha

Amgen's Label Expansion Application for Prolia Gets FDA Nod

Amgen (AMGN) announces FDA approval for its regulatory application seeking label expansion for Prolia.

  • on Zacks.com

Fifth Third Bancorp and Celgene: Top Losses on May 21

After a brief pullback last week, Fifth Third Bancorp opened lower on Monday and declined to one-month low price levels.

  • on MarketRealist.com

Valeant Pharmaceuticals Can Still Go Higher - Cramer's Lightning Round (5/21/18)

Valeant Pharmaceuticals Can Still Go Higher - Cramer's Lightning Round (5/21/18)

  • on Seeking Alpha

Orbimed Advisors Llc Buys Bristol-Myers Squibb Company, ARMO BioSciences Inc, Tenet Healthcare ...

Orbimed Advisors Llc Buys Bristol-Myers Squibb Company, ARMO BioSciences Inc, Tenet Healthcare Corp, Sells Eli Lilly and Co, Cigna Corp, Amgen Inc

  • on GuruFocus.com

Tracking David Tepper's Appaloosa Management Portfolio - Q1 2018 Update

Tracking David Tepper's Appaloosa Management Portfolio - Q1 2018 Update

  • on Seeking Alpha

Esmya Restriction In Europe Could Handcuff Allergan

Esmya Restriction In Europe Could Handcuff Allergan

  • on Seeking Alpha

Private Capital Buys CBIZ, Allergan, SpartanNash

Private Capital Buys CBIZ, Allergan, SpartanNash

  • on GuruFocus.com

MeiraGTx Aims For $86 Million U.S. IPO

MeiraGTx Aims For $86 Million U.S. IPO

  • on Seeking Alpha

New Migraine Drugs Offer Hope to Sufferers

The FDA has approved a new drug called Aimovig that is touted as the first treatment designed specifically to prevent migraines.

  • on The Wall Street Journal

Top Research Reports for Walmart, AT&T & Novo Nordisk

Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), AT&T (T) and Novo Nordisk (NVO).

  • on Zacks.com

Amgen's first mover advantage with Aimovig bodes well - analysts

Amgen's first mover advantage with Aimovig bodes well - analysts

  • on Seeking Alpha

Investors bullish on biotechs after Trump drug pricing speech

Investors bullish on biotechs after Trump drug pricing speech

  • on Seeking Alpha

Eyelashes Enhancing Agents Market Growth Drivers 2018 | By Types, Curling, Lengthening, Volumizing, and others | Full Study by Current Industry Status | Phenomenal Grow at a CAGR of 5.83% |Detailed Analysis up to 2023

Eyelashes Enhancing Agents Market Growth Drivers 2018 | By Types, Curling, Lengthening, Volumizing, and others | Full Study by Current Industry Status | Phenomenal Grow at a CAGR of 5.83% |Detailed Analysis up to 2023

  • on Heraldkeeper

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

  • on PR Newswire - PRF

Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne

Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne

  • on GlobeNewswire

Depression Screening Market Expected To Grow at a CAGR of 6.20% during the Forecast Period 2017-2023 | Exclusively Available at MarketResearchFuture.com

Depression Screening Market Expected To Grow at a CAGR of 6.20% during the Forecast Period 2017-2023 | Exclusively Available at MarketResearchFuture.com

  • on Heraldkeeper

Axovant Strengthens Management Team and Completes Organizational Restructuring in Preparation for Pipeline Expansion

Axovant Strengthens Management Team and Completes Organizational Restructuring in Preparation for Pipeline Expansion

  • on GlobeNewswire

Antiulcerant Drugs: Global Markets to 2022

Antiulcerant Drugs: Global Markets to 2022

  • on PR Newswire - PRF

Global Cystic Fibrosis Therapeutics Market Growth Opportunities: Alcresta Therapeutics Inc, Teva Pharmaceutical Industries Ltd

Global Cystic Fibrosis Therapeutics Market Growth Opportunities: Alcresta Therapeutics Inc, Teva Pharmaceutical Industries Ltd

  • on marketresearch.biz

Otoscope Devices Market is Projected to Reach US $3.5 Billion By 2024

Otoscope Devices Market is Projected to Reach US $3.5 Billion By 2024

  • on Heraldkeeper

Aesthetic Devices Market is Forecast to Cross US$ 18 Billion By 2023

Aesthetic Devices Market is Forecast to Cross US$ 18 Billion By 2023

  • on Heraldkeeper

Otoscope Devices Market is Projected to Reach US $3.5 Billion By 2024

Otoscope Devices Market is Projected to Reach US $3.5 Billion By 2024

  • on Heraldkeeper

Dumping Syndrome Market, Trends, Absolute Opportunity and Value Chain 2018-2023

Dumping Syndrome Market, Trends, Absolute Opportunity and Value Chain 2018-2023

  • on Heraldkeeper

Gastric Bypass Market will reach at a CAGR of 6.1% from 2018 to 2023

Gastric Bypass Market will reach at a CAGR of 6.1% from 2018 to 2023

  • on Heraldkeeper

Global Bone Cancer Diagnosis and Therapeutics Market 2018 Share, Trend, Segmentation and Forecast to 2023

Global Bone Cancer Diagnosis and Therapeutics Market 2018 Share, Trend, Segmentation and Forecast to 2023

  • on Heraldkeeper

Global Implantable Drug Delivery Devices Market Growth Opportunities: Arrow International, Theragenics Corporation

Global Implantable Drug Delivery Devices Market Growth Opportunities: Arrow International, Theragenics Corporation

  • on marketresearch.biz

Glaucoma Market 2018 Global Analysis, Opportunities and Forecast To 2021

Glaucoma Market 2018 Global Analysis, Opportunities and Forecast To 2021

  • on Heraldkeeper

Saphris (Allergan/Lundbeck/Meiji Seika) Drug Market Overview 2018 - ResearchAndMarkets.com

Saphris (Allergan/Lundbeck/Meiji Seika) Drug Market Overview 2018 - ResearchAndMarkets.com

  • on BusinessWire - BZX

Global Nasal Drops Market analysis 2018 and forecasts to 2025

Global Nasal Drops Market analysis 2018 and forecasts to 2025

  • on Heraldkeeper

Antibacterial Drugs Market is Expected to Grow US$ 38 Billion By 2023

Antibacterial Drugs Market is Expected to Grow US$ 38 Billion By 2023

  • on Financeswire

Physician Dispensed Cosmeceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Physician Dispensed Cosmeceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

  • on PR Newswire - PRF

United States : The Carlyle Group and Pharmaceutical Industry Veterans Launch Millicent Pharma with Acquisition of Femring

United States : The Carlyle Group and Pharmaceutical Industry Veterans Launch Millicent Pharma with Acquisition of Femring

  • on Euclid Tenders Info

Allergan PLC

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded on in 1984 and is headquartered in Dublin, Ireland. (See Full Profile)

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 25 Full Ratings

How Johnson & Johnson Stock Performed in 1Q18

  • on MarketRealist.com

Canaccord Sees An 'Intriguing Setup' In Biohaven Following Reaction To Phase 3 News

  • on Benzinga.com

Allergan Considering All Strategic Options 'With A Sense Of Urgency'

  • on Benzinga.com

Competitors

Name Chg % Market Cap
Abbott Laboratories -1.26% $109.35B
Merck & Co. Inc. -0.48% $158.97B
Zoetis Inc. -0.83% $40.48B
Mylan N.V. -1.07% $20.3B
Competitor Data Provided By

Partner Content